Department of Cardiology, National Heart Centre, 17 Third Hospital Avenue, Singapore.
Singapore Med J. 2009 May;50(5):534-7.
Surgical aortic valve replacement (AVR) is the standard of care for patients with symptomatic severe aortic stenosis (AS), providing relief of symptoms and prolonging survival. However, many patients are either denied or not offered surgery due to high surgical risk or non-operability for open AVR. The technology of percutaneous aortic valve implantation emerged in 2002, and has since evolved rapidly with satisfactory results. Currently, almost all the procedures are performed predominantly in Europe and North America. The first-in-Asia percutaneous transcatheter aortic valve implantation via the transfemoral route is described. A 77-year-old man with symptomatic severe AS and at high surgical risk was successfully treated, with sustained clinical improvement and satisfactory haemodynamic results at 30-day follow-up.
经导管主动脉瓣置换术(TAVR)是有症状的重度主动脉瓣狭窄(AS)患者的标准治疗方法,可缓解症状并延长生存期。然而,由于手术风险高或无法进行开放式 AVR,许多患者被拒绝或未接受手术。经皮主动脉瓣植入技术于 2002 年问世,此后发展迅速,效果令人满意。目前,几乎所有的手术主要在欧洲和北美进行。本文介绍首例经股动脉途径行经皮主动脉瓣植入术(TAVI)亚洲首例。一位 77 岁的男性,有症状的严重 AS 且手术风险高,成功接受了治疗,在 30 天随访时持续临床改善,血流动力学结果满意。